GPR120/FFAR4: A Potential New Therapeutic Target for Inflammatory Bowel Disease

Di Petrillo, Amalia

First

Writing - Original Draft Preparation

;Kumar, Amit

Second

Writing - Original Draft Preparation

;Onali, Sara

Writing - Review & Editing

;Favale, Agnese

Penultimate

Writing - Review & Editing

;Fantini, Massimo Claudio

Last

Writing - Original Draft Preparation

2023-01-01

---

Abstract

Inflammatory bowel disease, whose major forms are Crohn's disease and ulcerative colitis, is characterized by chronic inflammation of the gut due to the loss of tolerance toward antigens normally contained in the gut lumen. G protein-coupled receptor (GPR) 120 has gained considerable attention as a potential therapeutic target for metabolic disorders due to its implication in the production of the incretin hormone glucagon-like peptide 1 and the secretion of cholecystokinin. Recent studies have also highlighted the role of GPR120 in regulating immune system activity and inflammation. GPR120, expressed by intestinal epithelial cells, proinflammatory macrophages, enteroendocrine L cells, and CD4(+) T cells, suppresses proinflammatory and enhances anti-inflammatory cytokine production, suggesting that GPR120 might have a pivotal role in intestinal inflammation and represent a possible therapeutic target in inflammatory bowel disease. This narrative review aims at summarizing the role of GPR120 in the maintenance of intestinal homeostasis through the analysis of the most recent studies.